Simvastatin-Mediated Nrf2 Activation Induces Fetal Hemoglobin and Antioxidant Enzyme Expression to Ameliorate the Phenotype of Sickle Cell Disease
Sickle cell disease (SCD) is a pathophysiological condition of chronic hemolysis, oxidative stress, and elevated inflammation. The transcription factor Nrf2 is a master regulator of oxidative stress. Here, we report that the FDA-approved oral agent simvastatin, an inhibitor of hydroxymethyl-glutaryl...
Saved in:
Main Authors: | Caixia Xi (Author), Chithra Palani (Author), Mayuko Takezaki (Author), Huidong Shi (Author), Anatolij Horuzsko (Author), Betty S. Pace (Author), Xingguo Zhu (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Analysis of sickle hemoglobin
by: A Shrestha, et al.
Published: (2013) -
Phenotypic expression of HbO Indonesia in two Indian families and its interaction with sickle hemoglobin
by: Amar Das Gupta, et al.
Published: (2017) -
Hemoglobin and End-Organ Damage in Individuals with Sickle Cell Disease
by: William B. Ershler, MD, et al.
Published: (2023) -
Establishing sickle cell diagnostics in Malawi using hemoglobin electrophoresis
by: J.B. Heimlich, et al.
Published: (2016) -
Keap1-Nrf2 Heterodimer: A Therapeutic Target to Ameliorate Sickle Cell Disease
by: Waseem Chauhan, et al.
Published: (2023)